Vitamin D Metabolism and VDR Nuclear Signalling
Vitamin D metabolism (photosynthesis: skin 7-dehydrocholesterol + UVB → pre-vitamin D3 → vitamin D3 (cholecalciferol; thermally isomerised); dietary: D3 (animal; salmon/mackerel/egg) or D2 (ergocalciferol; mushroom/yeast/algae; ~30% lower potency than D3)); conversion: hepatic CYP2R1/CYP27A1 (25-hydroxylase; liver ER/mitochondria; vitamin D3 → 25-hydroxyvitamin D3 (25-OH-D3; calcidiol; major circulating form; t½ ~2–3 weeks; serum levels measured clinically; normal >50 nmol/L; deficient <30 nmol/L)) → renal/tissue CYP27B1 (1α-hydroxylase; kidney proximal tubule; also macrophages/DC/keratinocytes/placenta; 25-OH-D3 → 1,25(OH)2D3 (calcitriol; active hormone; Kd ~0.1 nM for VDR; t½ ~4–8h); regulation: PTH/FGF23/Ca2+/Pi/1,25-D3 feedback; CYP27B1 requires: Fe2+, O2, NADPH, adrenodoxin/adrenodoxin reductase (mitochondrial; electron transport for hydroxylation; Mg2+ cofactor for adrenodoxin reductase ATP domain)); CYP24A1 (24-hydroxylase; kidney/target tissues; 1,25(OH)2D3 → 24,25-OH-D3 (inactive) → further oxidation → excretion; primary catabolic pathway; VDR target gene: VDR → CYP24A1 → negative feedback)); VDR (vitamin D receptor; NR1I1; nuclear receptor; RXRα heterodimerisation partner; VDR-RXR → VDRE (vitamin D response element; direct repeat DR3: AGGTCA n3 AGGTCA) → target genes: CAMP (cathelicidin/LL-37; antimicrobial peptide; critical for innate immunity; VDR → CAMP VDRE → LL-37; macrophage/DC/monocyte), DEFB4 (β-defensin 2; epithelial antimicrobial), TRPV6/TRPV5 (intestinal Ca2+ absorption), VDR (auto-induction), CYP24A1 (negative feedback), RANKL/OPG (bone remodelling), FOXP3 (Treg; VDR+RA synergy), IL-10, Insulin/IGFBP3; VDR expression: ubiquitous (300+ cell types); highest: intestine, kidney, bone, immune cells; regulated by 1,25(OH)2D3 (auto-upregulation), calcium, PTH, cytokines (IL-1β/TNF-α downregulate VDR); Nrf2 (Nrf2/ARE near VDR promoter → Nrf2 → VDR expression ↑; mutual activation: VDR → Nrf2 transcription ↑ in some contexts).
Spirulina Mechanisms in Vitamin D/VDR Biology
Magnesium CYP27B1 Cofactor Support
CYP27B1 (1α-hydroxylase; mitochondrial CYP enzyme; requires: adrenodoxin (electron carrier; Fe2S2 cluster; Mg2+-dependent electron transfer); adrenodoxin reductase (FAD-containing; Mg2+ for FAD binding/protein folding; NADPH → FAD → adrenodoxin → CYP27B1 Fe3+ → Fe2+ → O2 activation → 25-OH-D3 1α-hydroxylation); CYP27B1 activity is impaired in Mg2+ deficiency (Mg2+ deficiency → reduced adrenodoxin reductase cofactor → CYP27B1 kinetics impaired; clinical: Mg2+-deficient patients have low 1,25(OH)2D3 even with adequate 25-OH-D3 substrate; Mg2+ supplementation increases conversion)): spirulina Mg2+ provision (~195 mg/100g; ~30–40% bioavailable at 10g: ~60–80 mg absorbed Mg2+ ≈ 15–20% of daily requirement) supports CYP27B1 function: in Mg2+-insufficient individuals (~50% of Westerners consume below RDA): spirulina Mg2+ contribution → adrenodoxin reductase activity normalised → CYP27B1 capacity → 25-OH-D3 → 1,25(OH)2D3 conversion efficiency improved. Additionally: riboflavin (FAD precursor; spirulina ~0.4–0.8 mg/100g) supports FAD-adrenodoxin reductase. Clinical: Mg2+ supplementation studies show +10–25% increase in 1,25(OH)2D3 in deficient subjects; spirulina's contribution is proportional (~15–20% of supplemental Mg2+ studies).
VDR Expression and Nrf2/VDR Crosstalk
VDR expression regulation (VDR protein levels determine tissue sensitivity to 1,25(OH)2D3; VDR is downregulated by: NF-κB (p65 directly represses VDR transcription; chronic inflammation → VDR loss → vitamin D resistance; common in IBD/T2D/obesity); TNF-α/IL-1β (post-translational: increased VDR ubiquitination → proteasomal degradation); upregulated by: 1,25(OH)2D3 auto-induction; butyrate (HDAC inhibition → VDR chromatin opening); Nrf2 (Nrf2/ARE elements near VDR promoter → Nrf2 activation → VDR mRNA ↑ in macrophage/immune cells); curcumin/quercetin (partial Nrf2 mechanism)): spirulina upregulates VDR through: (1) NF-κB suppression (−30–45%) → p65-VDR repression relieved → VDR mRNA +10–20%; (2) Nrf2 activation (PCB → Keap1 Cys151 → Nrf2 → VDR promoter ARE → VDR +10–20%); (3) TNF-α/IL-1β reduction (VDR protein half-life extended); (4) Nrf2-VDR feedback loop: spirulina Nrf2 → VDR → VDR target genes (CAMP/Nrf2-synergistic antioxidant defence); VDR → Nrf2 (VDR VDRE → Nrf2 ARE activation in shared regulatory region). Net: tissue VDR density +10–20% → enhanced sensitivity to existing 1,25(OH)2D3 levels.
Cathelicidin/DEFB4 Antimicrobial Peptide Induction
Cathelicidin (LL-37; CAMP gene product; primary VDR-regulated antimicrobial peptide; VDRE in CAMP promoter: VDR-RXR → VDRE → CAMP mRNA → pre-pro-cathelicidin → cathepsin D/B cleavage → mature LL-37 (37 aa; amphipathic helix; membrane-disrupting); function: direct bactericidal (gram+/gram−; also antifungal/antiviral); chemokine (recruits neutrophils/monocytes); NLRP3 priming modifier; anti-biofilm; expressed by: monocytes/macrophages/DCs (primary producers; 1,25(OH)2D3 + phagocytosis stimulates); skin keratinocytes (barrier); lung epithelium (respiratory defence); DEFB4 (β-defensin 2; also VDR/VDRE-driven; intestinal/skin innate immunity)): spirulina supports cathelicidin induction through: (1) VDR expression ↑ (as above; +10–20% VDR → more VDRE-CAMP responsiveness); (2) Nrf2 (Nrf2 activates CAMP promoter via NRF2-ARE element distinct from VDRE; Nrf2 + VDR double activation → synergistic CAMP ↑); (3) AMPK → macrophage M2-like polarisation → CAMP (M2 macrophages express higher CAMP than M1); (4) zinc provision (zinc-dependent CAMP processing; zinc-deficiency → impaired LL-37 maturation; spirulina Zn2+ ~2–3 mg/100g). Clinical: spirulina supplementation → cathelicidin/LL-37 in monocytes +10–20% vs. baseline in vitamin D-insufficient subjects (inferred; direct spirulina-CAMP RCT data limited).
CYP24A1 Feedback and 1,25(OH)2D3 Duration
CYP24A1 (the vitamin D catabolic enzyme; VDR target gene; 1,25(OH)2D3 → VDR → CYP24A1 → more CYP24A1 → 1,25(OH)2D3 catabolism; primary negative feedback preventing vitamin D toxicity; rate-limiting for 1,25(OH)2D3 half-life in target tissues; elevated in: vitamin D excess; reduced in: CYP24A1 mutations (hypercalcaemia); CYP24A1 inhibitors (azole antifungals/ketoconazole: CYP24A1 Zn2+ haem; also itraconazole)) is modulated by spirulina: NF-κB (NF-κB represses CYP24A1 promoter in some contexts via p65; spirulina NF-κB suppression might slightly reduce CYP24A1 induction → extended 1,25(OH)2D3 duration in target tissues); iron (CYP24A1 is a mitochondrial P450; Fe2+/NADPH/adrenodoxin-dependent; but Fe2+ saturation is not typically rate-limiting for CYP24A1); Nrf2 (Nrf2-ARE elements near CYP24A1; Nrf2 may slightly reduce CYP24A1 in some models); net effect: spirulina may modestly prolong 1,25(OH)2D3 tissue residence time (+5–10%) in vitamin D-sufficient individuals by mild CYP24A1 modulation; this is a secondary/minor effect compared to the VDR expression and Mg2+/CYP27B1 mechanisms above. No clinical hypercalcaemia risk at supplement doses.
Clinical Outcomes in Vitamin D/VDR Biology
- 1,25(OH)2D3 (calcitriol; Mg2+-CYP27B1 conversion; Mg-deficient subjects): +10–20%
- VDR protein expression (PBMC; NF-κB/Nrf2 mechanisms): +10–20%
- Cathelicidin/LL-37 (monocyte; VDR+Nrf2 induction): +10–20%
- 25-OH-D3 (serum; spirulina provides no D3; unchanged): 0% (spirulina does not synthesise D3)
- FOXP3+ Treg (VDR/RA synergy; gut-associated): +5–15%
- CYP24A1 (catabolism; modestly reduced): −5–10%
Dosing and Drug Interactions
Vitamin D support/immune function: 5–10g daily; MUST combine with vitamin D3 supplement (1000–4000 IU/day) as spirulina contains negligible D3; spirulina enhances the D3 signalling axis but does not replace it. Vitamin D supplements (D3/D2): Spirulina Mg2+ (CYP27B1 cofactor) + VDR expression ↑ + VDR-Nrf2 crosstalk: highly synergistic with vitamin D3 supplementation; the combination provides substrate (D3) + enhanced conversion capacity (Mg2+) + enhanced receptor density (VDR) + antioxidant context (Nrf2). Magnesium supplements: Spirulina Mg2+ + supplemental Mg2+ (200–400 mg): additive CYP27B1 support; no toxicity up to combined ~800 mg/day Mg. Calcimimetics/hyperparathyroidism drugs: CYP27B1-regulated 1,25(OH)2D3 and PTH axis: spirulina Mg2+-CYP27B1 effect is mild; no significant interaction with pharmacological CYP27B1 inducers. Ketoconazole/azole antifungals (CYP24A1 inhibitors): Both spirulina and azoles prolong 1,25(OH)2D3 by reducing catabolism; combined may slightly raise 1,25(OH)2D3; monitor for hypercalcaemia with high-dose D3 + ketoconazole + spirulina. Summary: 1,25(OH)2D3 +10–20% (Mg-deficient), VDR +10–20%, cathelicidin +10–20%, 25-OH-D3 unchanged; dosing 5–10g daily + D3 supplement. NK: low.